GRPH Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 mar 2024 @ 21:00):

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States...

Stats
Dagens volum	299 406
Gjennomsnittsvolum	40 955.00
Markedsverdi	185.19M
EPS	$-0.400 ( 2024-03-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.210
ATR14	$0.0600 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-28	Drapkin Kimberlee C	Buy	40 000	Stock Option (right to buy)
2023-07-28	Drapkin Kimberlee C	Buy	0
2023-07-19	Viney Joanne L.	Buy	20 000	Stock Option (right to buy)
2023-07-19	Porteus Matthew	Buy	20 000	Stock Option (right to buy)
2023-07-19	Karsen Perry A	Buy	20 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 36 276 632 \| Sell: 68 481 989

Volum Korrelasjon

Lang: 0.15 (neutral)

Kort: 0.77 (moderate)

Signal:(51.506) Neutral

Graphite Bio, Inc. Korrelasjon

10 Mest positive korrelasjoner
SGLB	0.895
MTEX	0.893
ZENV	0.882
GRIN	0.88
PIII	0.874
RIVN	0.872
LCAP	0.868
SOPA	0.868
LAWS	0.865
OP	0.865

10 Mest negative korrelasjoner
DYNT	-0.95
FTFT	-0.949
DGLY	-0.935
ATNX	-0.924
CRNC	-0.921
CFRX	-0.918
FGEN	-0.914
IPHA	-0.913
CSWI	-0.912
ECOR	-0.912

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Graphite Bio, Inc. Korrelasjon - Valuta/Råvare

-0.43
( neutral )

0.00
( neutral )

-0.34
( neutral )

0.00
( neutral )

0.67
( moderate )

Graphite Bio, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-2.41M (0.00 %)
EPS:	$-2.19

FY	2023
Omsetning:	$0
Bruttogevinst:	$-2.41M (0.00 %)
EPS:	$-2.19

FY	2022
Omsetning:	$0
Bruttogevinst:	$-8.35M (0.00 %)
EPS:	$-1.760

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.45

Financial Reports:

No articles found.

Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.